Progressive Symmetric Erythrokeratodermia - An Overview

What Is Progressive Symmetric Erythrokeratodermia?

Progressive symmetric erythrokeratodermia (PSEK) is a rare hereditary skin condition characterized by the symmetrical development of hyperkeratotic, erythematous plaques that mostly affect the face, buttocks, and extremities, avoiding the trunk. These plaques appear shortly after birth. PSEK, initially reported by Darier in 1911, belongs to a class of diseases called erythrokeratodermia, which combines erythema (redness) and hyperkeratosis (skin thinning). In the early stages of the disease, the lesion will have keratotic plaques on an erythematous base and stay in one spot. It usually targets more specific skin surfaces, such as the face, buttocks, and extremities, and is distributed symmetrically around joints.

This condition is typically not linked to any further clinical symptoms or signs of the mind or body. Other names for this illness include erythrokeratodermia variabilis et progressiva, progressive symmetric erythrokeratodermia, progressive symmetric erythrokeratodermia of Gottron, and Darier-Gottron syndrome. The lesions often appear early in infancy and worsen with time. The lesions may regress partially or stay constant after puberty. Oral retinoids are the recommended treatment for erythrokeratodermias. The adverse consequences are what restrict their use, particularly in younger patients. Although there have been cases of clinical improvement, therapy interruption is likely to result in relapse.

What Are the Signs and Symptoms of Progressive Symmetric Erythrokeratodermia?

PSEK usually appears in the early stages of life, usually in the first year. The defining feature of this condition is the presence of symmetric, erythematous, hyperkeratotic plaques. The typical locations for these plaques to develop are the cheeks, buttocks, dorsum of hands and feet, wrists, elbows, knees, ankles, and extensor surfaces of the limbs. PSEK plaques frequently have raised, scaly surfaces and are well-defined.

Different patients will have varying degrees of erythema; some will be extremely red, while others will have more noticeable hyperkeratosis. The breakdown of the skin barrier can cause the skin to become thicker and rougher, which can cause discomfort and perhaps lead to secondary infections. One characteristic that sets PSEK apart is symmetry, and lesions appear in the exact locations on both sides of the body. In some cases, the nails will be swollen and discolored in a yellowish manner; certain nail plates also have transverse ridges.

Histopathological examination shows hyperkeratosis (increased thickness of the outer layer of the skin), acanthosis (thickening of the skin), parakeratosis (the presence of nucleated keratinocytes in the outer layer of the skin), elongation of rete ridges, extension of dermal papillae, and a mild lymphocytic infiltration around the superficial blood vessels with mild spongiosis.

What Causes Progressive Symmetric Erythrokeratodermia?

Several genes related to keratinocyte differentiation and skin barrier function have been implicated in PSEK's genetic basis. GJB4, which codes for the protein connexin 30.3, a component of gap junctions in the epidermis, is one of the main genes involved. This gene's mutations cause aberrant keratinization and plaque development by interfering with cellular communication.

PSEK has also been linked to mutations of the loricrin and keratin genes, which may disrupt epidermal differentiation. Loricrin is a crucial structural element of the epidermis's cornified cell envelope and aids in the granule production of keratohyalin. Keratins contribute to the preservation of the skin's resilience and structural integrity. Hyperkeratotic plaques result from mutations in these genes, which lead to impaired production of the epidermal barrier and increased vulnerability to external stimuli.

PSEK is inherited in an autosomal dominant manner, which means that the condition can be caused by a single mutated copy of the gene in each cell. Other cases point to incomplete penetrance and varied expressivity, suggesting that not all people with the mutation would experience the illness or that symptoms may vary in severity.

How Is Progressive Symmetric Erythrokeratodermia Diagnosed?

The primary methods of diagnosing PSEK are clinical examination and identifying distinctive skin lesions. Dermatologists rely on the hyperkeratotic plaques' symmetrical distribution, early infancy onset, and chronic, progressive character. The presence of palmoplantar keratoderma may also aid in the diagnosis. Imaging studies and testing have no diagnostic value. Gene sequencing and mutation testing help identify a mutation in the GJB4 gene.

What Is the Treatment for Progressive Symmetric Erythrokeratodermia?

PSEK has no known cure; instead, care aims to control symptoms and enhance quality of life. Emollients and keratolytic treatments are frequently utilized to lessen hyperkeratosis and keep skin hydrated. By using these topical treatments regularly, plaques can be softened, and discomfort can be reduced.

Tropical Therapies:

Emollients can be used alone or with other treatments to hydrate the skin. Retinoids like Tretinoin and Tazarotene cream show promise in reducing hyperkeratosis. However, these agents need to be used under medical supervision because they can irritate. Salicylic acid ointment, Tretinoin ointment, keratolytic, and corticosteroids are typically used with varying degrees of success. It is preferable to combine emollients with retinoids or keratolytics. While long-term use of topical corticosteroids is discouraged because of potential side effects, they can occasionally relieve inflammation and erythema.

Systemic Therapies:

• Retinoids: Retinoids are the preferred course of therapy for generalized PSEK. Multiple PSEK patients showed improvement, but recurrence occurred once retinoids were stopped. Side effects such as mucocutaneous dryness, teratogenicity, and possible liver damage require cautious patient selection and monitoring. Being pregnant is a complete contraindication for retinoid use.

• H1 Antihistamine: H1 antihistamines used orally, such as Hydroxyaine, can reduce itching.

• Phototherapy: Psoralen plus ultraviolet A (PUVA) therapy has effectively treated PSEK.

Psychosocial Support: The mental well-being of patients may be significantly impacted by PSEK because of its evident and persistent character. Due to their appearance, children and adults with PSEK may feel socially isolated, which can cause mental discomfort and low self-esteem. Counseling and psychological support might be helpful for patients and their families. In addition to offering valuable tools, support groups, and patient organizations promote a sense of belonging and shared experiences. Improving quality of life requires educating patients and caregivers about the illness, how to treat it, and coping mechanisms.

Conclusion

Progressive symmetric erythrokeratodermia (PSEK) is a sporadic genetic skin disorder with significant clinical and psychosocial implications. This condition appears in the early stages of life and has characteristic features such as the presence of symmetric, erythematous, and hyperkeratotic plaques. Although there is no cure, advancements in medicinal technologies and genetic research offer hope for better management and potential future treatments.